Literature DB >> 27932871

Efficacy and safety outcomes of fractional flow reserve in guiding clinical therapy of non-ST-segment elevation myocardial infarction compared with angiography alone in elderly Chinese patients.

Zhao Zhang1, Ke Li1, Jinwen Tian1.   

Abstract

OBJECTIVE: Fractional flow reserve (FFR) is an innovative method for evaluating the physiological significance of a coronary stenosis, but its validity is less certain in patients with non-ST-segment elevation myocardial infarction (NSTEMI). It is important to assess whether FFR is effective and safe in patients, especially elderly Chinese patients, with NSTEMI. As the first one in China, the purpose of this study was to establish the efficacy and safety outcomes of FFR in guiding clinical therapy of NSTEMI compared with angiography alone in elderly Chinese patients. PATIENTS AND METHODS: This prospective randomized controlled study included 220 patients with NSTEMI older than 65 years. Patients were assigned in a ratio of 1:1 to the FFR-guided group and the angiography-guided group, and their outcomes were evaluated after 1 year of follow-up.
RESULTS: The mean age of the patients was 70±3.6 years, and 69.6% were men. Baseline characteristics of the patients had no differences between the two groups (P>0.05 for all). No differences in adverse events, including major adverse cardiovascular event, major adverse cardiovascular and cerebrovascular event, cardiovascular death, nonfatal myocardial infarction, heart failure, stroke, transient ischemic attack, all-cause mortality, contrast nephropathy, and major bleeding, was observed between the two groups during the follow-up (P>0.05 for all). The number of patients receiving medical therapy alone in the FFR-guided group was significantly more than that in the angiography-guided group (P<0.05).
CONCLUSION: Compared with angiography-guided standard therapy, FFR reduced the application of percutaneous coronary intervention and obtained similar outcomes, demonstrating that FFR was effective and safe in guiding clinical therapy of NSTEMI in elderly Chinese patients.

Entities:  

Keywords:  elderly Chinese patients; fractional flow reserve; non-ST-segment elevation myocardial infarction

Mesh:

Year:  2016        PMID: 27932871      PMCID: PMC5135069          DOI: 10.2147/CIA.S123735

Source DB:  PubMed          Journal:  Clin Interv Aging        ISSN: 1176-9092            Impact factor:   4.458


Introduction

Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide.1,2 Angiography is the current standard method applied for clinical therapy of CAD. However, visual assessment of the anatomical severity of a coronary stenosis is subjective and correlates poorly with physiological significance, potentially resulting in inappropriate therapy strategy.3 Fractional flow reserve (FFR) is an innovative method for evaluating the physiological significance of a coronary stenosis and is defined as the ratio of maximal blood flow in a stenotic artery to normal maximal flow in the absence of a stenosis. International guidelines have recognized the value of FFR in guiding clinical therapy in patients with stable CAD.4,5 However, the validity of FFR is less certain in patients with non-ST-segment elevation myocardial infarction (NSTEMI), and it is an essential issue to assess whether FFR is effective and safe in these patients.6 Age and ethnicity-related changes in cardiovascular structure and function have an inevitable effect on FFR, and the role of FFR in clinical therapy of elderly Chinese patients with NSTEMI has not been explored. As the first one in China, the purpose of this study was to establish the efficacy and safety outcomes of FFR in guiding clinical therapy of NSTEMI compared with angiography alone in elderly Chinese patients.

Patients and methods

Participants

This prospective randomized controlled study included 220 patients with NSTEMI older than 65 years of age and was performed in the Department of Cardiology from September 2013 to June 2016. NSTEMI was diagnosed based on acute ischemic symptoms and abnormal myocardial markers but without ST-segment elevation on the electrocardiogram. Exclusion criteria were as follows: 1) ongoing ischemic symptoms after medical therapy; 2) cardiogenic shock or hemodynamic instability; 3) intolerance to antiplatelet drugs; 4) ineligibility for percutaneous coronary intervention (PCI); 5) CAD <30% severity; 6) highly tortuous or calcified coronary arteries; 7) noncoronary cardiosurgery; and 8) life expectancy <1 year. This study was approved by the ethics committee of Chinese People’s Liberation Army General Hospital and conducted in line with the Declaration of Helsinki. All patients enrolled in this study provided their written informed consent.

Processes

In the clinical medical and invasive therapy, evidence-based guidelines were followed.7–9 Angiography was performed using standard catheterization room equipment and evaluated visually by an experienced clinician who determined the therapy strategy based on the coronary stenosis severity (stenosis ≤ or >70% of reference vessel diameter [50% for left main]). Patients were assigned in a ratio of 1:1 to the FFR-guided group and the angiography-guided group using random digits in a randomized block design. After coronary dilation caused by intravenous infusion of adenosine (140 µg/kg/min), patients in the FFR-guided group had FFR measured using a pressure-sensitive coronary guidewire (St Jude Medical, Inc., St Paul, MN, USA). A cutoff point of 0.80 was the standard selecting PCI (≤0.80) or medical therapy alone (>0.80).

Outcomes

The following outcomes were evaluated after 1 year of follow-up: 1) adverse events, including major adverse cardiovascular event defined as cardiovascular death, nonfatal myocardial infarction, or unplanned hospitalization for heart failure, major adverse cardiovascular and cerebrovascular event defined as cardiovascular death, nonfatal myocardial infarction, unplanned hospitalization for stroke, or transient ischemic attack, all-cause mortality, contrast nephropathy, and major bleeding, and 2) therapy strategies (PCI or medical therapy alone).

Statistics

Continuous data were presented as mean (standard deviation) or median (interquartile range), and categorical data were presented as number (percentage). Continuous variables between the two groups were compared using Student’s t-test or Mann–Whitney U test, and categorical variables between the two groups were compared using Chi-square test. All analyses were two tailed at the 5% significance level using Statistical Package for the Social Sciences Version 17.0 software (SPSS Inc., Chicago, IL, USA).

Results

The mean age of all patients were 70±3.6 years, and 69.6% were men. As shown in Table 1, baseline characteristics of patients had no differences between the two groups (P>0.05 for all). As shown in Table 2, no differences in adverse events including major adverse cardiovascular event, major adverse cardiovascular and cerebrovascular event, cardiovascular death, nonfatal myocardial infarction, heart failure, stroke, transient ischemic attack, all-cause mortality, contrast nephropathy, and major bleeding were observed between the two groups during the follow-up (P>0.05 for all). Based on angiography alone, there were nine patients receiving medical therapy alone in the FFR-guided group and no difference with patients in the angiography-guided group (P>0.05). Based on FFR, the other six patients (5.5%) received medical therapy alone in the FFR-guided group. Patients receiving medical therapy alone in the FFR-guided group (15 patients) were significantly more than those in the angiography-guided group (six patients; P<0.05).
Table 1

Baseline characteristics of patients in clinical therapy guided by FFR or angiography alone

CharacteristicsFFR-guided group(n=110)Angiography-guided group(n=110)P-value
Age, years, mean ± SD70±3.770±3.40.267
Men, n (%)75 (68.2)78 (70.9)0.660
Smoking, n (%)0.908
 Current29 (26.4)31 (28.2)
 Former41 (37.3)38 (34.5)
 Never40 (36.4)41 (37.3)
Previous MI, n (%)24 (21.8)23 (20.9)0.869
Heart failure, n (%)2 (1.8)1 (0.9)1.000
Hypertension, n (%)81 (73.6)83 (75.5)0.757
Diabetes mellitus, n (%)40 (36.4)36 (32.7)0.571
Hyperlipidemia, n (%)90 (81.8)93 (84.5)0.589
Peak troponin levels, n (%)
 >×5 upper limit of normal87 (79.1)82 (74.6)0.424
 >×10 upper limit of normal69 (62.7)64 (58.2)0.491
Procedural characteristics, n (%)
 Radial artery access95 (86.4)98 (89.1)0.538
 Aspirin110 (100.0)110 (100.0)
 Clopidogrel89 (80.9)86 (78.2)0.616
 Ticagrelor21 (19.1)24 (21.8)0.616
 Statin103 (93.6)105 (95.5)0.553
 Beta-blocker74 (67.3)73 (66.4)0.886
 CCB45 (40.9)49 (44.6)0.586
 Nitrates98 (89.1)96 (87.3)0.676
 LMWH101 (91.8)102 (92.7)0.801

Abbreviations: CCB, calcium channel blocker; FFR, fractional flow reserve; LMWH, low molecular weight heparin; MI, myocardial infarction; SD, standard deviation.

Table 2

Outcomes of patients in clinical therapy guided by FFR or angiography alone

OutcomesFFR-guided groupM(n=110)Angiography-guided group(n=110)P-value
Adverse events
 MACE9 (8.2)11 (10.0)0.639
 MACCE10 (9.1)13 (11.8)0.509
 Cardiovascular death4 (3.6)5 (4.5)0.734
 Nonfatal MI5 (4.5)7 (6.4)0.553
 Heart failure4 (3.6)5 (4.5)0.734
 Stroke0 (0)1 (0.9)1.000
 TIA1 (0.9)1 (0.9)1.000
 All-cause mortality9 (8.2)11 (10.0)0.639
 Contrast nephropathy0 (0)2 (1.8)0.477
 Major bleeding2 (1.8)3 (2.7)1.000
Therapy strategies0.039
 Medical therapy15 (13.6)6 (5.5)
 PCI95 (86.4)104 (94.5)

Notes: Data presented as n (%). MACE is defined as cardiovascular death, nonfatal MI, or unplanned hospitalization for heart failure; MACCE is defined as cardiovascular death, nonfatal MI, unplanned hospitalization for stroke, or TIA.

Abbreviations: FFR, fractional flow reserve; MACE, major adverse cardiac event; MACCE, major adverse cardiac and cerebral event; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

Discussion

The current standard method applied for clinical therapy of NSTEMI is angiography with visual interpretation of anatomical severity of a coronary stenosis. FFR is an innovative method evaluating the physiological significance of a coronary artery stenosis and is able to determine the therapy strategies. FFR is gradually applied in patients with stable CAD due to the approval of international guidelines. However, in patients, especially elderly Chinese patients, with NSTEMI, FFR-guided therapy is not the standard method, mainly because of lacking evidence. This study showed that FFR-guided therapy reduced the application of PCI and obtained similar outcomes compared with angiography alone, demonstrating that FFR was effective and safe in guiding clinical therapy of NSTEMI in elderly Chinese patients. FFR had important implications in advancing clinical therapy of stable CAD.10 Studies such as DEFER and FAME have confirmed the benefits of FFR in stable CAD to more precisely guide the clinical therapy.11,12 The validity of FFR is less clear in patients with acute coronary syndrome (ACS) due to the likelihood that coronary response to vasodilators may be decreased due to coronary obstruction. Coronary lesion of patients with ST-segment elevation myocardial infarction may limit the dilatation of coronary and the validity of FFR.13 However, FFR may be valuable in patients with NSTEMI because its lesion is typically nonocclusive thrombotic plaque rupture and subendocardial infarction with transient coronary dysfunction and preserved blood flow.14 Coronary reserve has been found to be similar in patients with stable angina and NSTEMI, which is consistent with preserved dilation ability in patients with stable ACS.14 A post hoc analysis of patients with stable ACS in the FAME study has suggested the validity of FFR.15 The FAMOUS-NSTEMI study has reported on the efficacy and safety of FFR-guided therapy in patients with NSTEMI.16 Uncertainty for FFR application was specifically addressed in elderly Chinese patients and similarly caused by lacking evidence. In a post hoc analysis of patients in the FAME study, Lim et al17 have highlighted that FFR-guided therapy was similarly beneficial irrespective of age. Results of this study also illustrated that FFR was feasible because it not only determined the decreased application of PCI but was also not associated with worse outcomes in elderly Chinese patients with NSTEMI. This study had several limitations. The sample size is relatively small, and the follow-up duration is relatively short in this study, so it is necessary to conduct large-scale studies with long follow-up periods to confirm the results obtained from this study.

Conclusion

This study confirmed that, compared with angiography-guided standard therapy, FFR reduced the application of PCI and obtained similar outcomes, demonstrating that FFR was effective and safe in guiding clinical therapy of NSTEMI in elderly Chinese patients.
  16 in total

1.  Guidelines on myocardial revascularization.

Authors:  William Wijns; Philippe Kolh; Nicolas Danchin; Carlo Di Mario; Volkmar Falk; Thierry Folliguet; Scot Garg; Kurt Huber; Stefan James; Juhani Knuuti; Jose Lopez-Sendon; Jean Marco; Lorenzo Menicanti; Miodrag Ostojic; Massimo F Piepoli; Charles Pirlet; Jose L Pomar; Nicolaus Reifart; Flavio L Ribichini; Martin J Schalij; Paul Sergeant; Patrick W Serruys; Sigmund Silber; Miguel Sousa Uva; David Taggart
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

2.  Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study.

Authors:  Nico H J Pijls; Pepijn van Schaardenburgh; Ganesh Manoharan; Eric Boersma; Jan-Willem Bech; Marcel van't Veer; Frits Bär; Jan Hoorntje; Jacques Koolen; William Wijns; Bernard de Bruyne
Journal:  J Am Coll Cardiol       Date:  2007-05-17       Impact factor: 24.094

3.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

4.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

5.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

6.  The impact of age on fractional flow reserve-guided percutaneous coronary intervention: a FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) trial substudy.

Authors:  Hong-Seok Lim; Pim A L Tonino; Bernard De Bruyne; Andy S C Yong; Bong-Ki Lee; Nico H J Pijls; William F Fearon
Journal:  Int J Cardiol       Date:  2014-09-20       Impact factor: 4.164

7.  Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation.

Authors:  Pim A L Tonino; William F Fearon; Bernard De Bruyne; Keith G Oldroyd; Massoud A Leesar; Peter N Ver Lee; Philip A Maccarthy; Marcel Van't Veer; Nico H J Pijls
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

8.  Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study.

Authors:  Jan-Willem E M Sels; Pim A L Tonino; Uwe Siebert; William F Fearon; Marcel Van't Veer; Bernard De Bruyne; Nico H J Pijls
Journal:  JACC Cardiovasc Interv       Date:  2011-11       Impact factor: 11.195

9.  Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction.

Authors:  N G Uren; T Crake; D C Lefroy; R de Silva; G J Davies; A Maseri
Journal:  N Engl J Med       Date:  1994-07-28       Impact factor: 91.245

10.  Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial.

Authors:  Jamie Layland; Keith G Oldroyd; Nick Curzen; Arvind Sood; Kanarath Balachandran; Raj Das; Shahid Junejo; Nadeem Ahmed; Matthew M Y Lee; Aadil Shaukat; Anna O'Donnell; Julian Nam; Andrew Briggs; Robert Henderson; Alex McConnachie; Colin Berry
Journal:  Eur Heart J       Date:  2014-09-01       Impact factor: 29.983

View more
  2 in total

1.  Prediction of 3D Cardiovascular hemodynamics before and after coronary artery bypass surgery via deep learning.

Authors:  Gaoyang Li; Haoran Wang; Mingzi Zhang; Simon Tupin; Aike Qiao; Youjun Liu; Makoto Ohta; Hitomi Anzai
Journal:  Commun Biol       Date:  2021-01-22

2.  Clinical Outcomes Following Hemodynamic Parameter or Intravascular Imaging-Guided Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: An Updated Systematic Review and Bayesian Network Meta-Analysis of 28 Randomized Trials and 11,860 Patients.

Authors:  Meng-Jin Hu; Jiang-Shan Tan; Lu Yin; Yan-Yan Zhao; Xiao-Jin Gao; Jin-Gang Yang; Yue-Jin Yang
Journal:  Front Cardiovasc Med       Date:  2022-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.